Rani Therapeutics announces preclinical data on RaniPill platform

Rani Therapeutics announced preclinical data supporting the safety and tolerability of the RaniPill drug delivery platform following 60-day repeat administration. In the 60-day good laboratory practices study in healthy animals, the RaniPill(R) capsule was well-tolerated with no treatment-related adverse events. “The preclinical data announced today are highly encouraging and we believe these data further validate the safety and tolerability of our RaniPill(R) drug delivery platform,” said Mir Hashim, PhD, Chief Scientific Officer of Rani. “Our platform has the potential to offer an oral delivery option for drugs otherwise only available as injections and is drug-agnostic with the opportunity for application across a wide range of biologics. The data from this 60-day GLP study further bolster the safety database supporting the RaniPill(R) capsule and enable the launch of longer-term clinical trials of Rani’s pipeline programs, including our Phase II study of RT-102 for osteoporosis which we plan to initiate in 2023.” The preclinical GLP study evaluated the safety and tolerability of the RaniPill drug delivery platform, following 60-day repeat oral administration of the test article, RT-100. RT-100 was well-tolerated with no treatment-related adverse events and all animals remained clinically healthy throughout the study.